IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00Inhibikase Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Provides Interim Update On '501' Bioequivalence Study Of IkT-001Pro
Brief: Inhibikase Therapeutics Inc - Does Not Hold Cash Deposits Or Lines Of Credit With Svb, And Does Not Otherwise Have A Business Relationship With Svb
Brief: Inhibikase Therapeutics Announces FDA Lifts Full Clinical Hold On IkT-148009
Inhibikase Therapeutics jumps after FDA lifts clinical hold on second lead drug study
Brief: Inhibikase Therapeutics Announces Closing Of $10 Million Concurrent Registered Direct Offering And Private Placement Priced At A Premium To Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Hess Corp, Monro, MarketAxess
U.S. STOCKS ON THE MOVE-Block Inc, Fennec, Inhibikase Therapeutics
Inhibikase Therapeutics soars as FDA lifts hold on Parkinson's drug trial
Brief: Inhibikase Therapeutics Announces FDA Has Lifted The Full Clinical Hold On Ikt-148009 In Parkinson's Disease
Brief: Inhibikase Therapeutics Announces Dosing Of First Subjects In Its '501' Bioequivalence Study Of Ikt-001Pro
Brief: Inhibikase Therapeutics Provides Update To FDA Clinical Hold Of IKT-148009 Programs
Inhibikase Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results, Highlights Recent Period Activity
Inhibikase Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kosmos Energy, Scisparc, Walgreens
U.S. STOCKS ON THE MOVE-IAA, Fluor, Oyster Point
Brief: Inhibikase Therapeutics Announces FDA Clinical Hold On Ikt-148009 Programs
Inhibikase slumps as FDA puts lead drug studies on hold